All Articles

A retrospective study conducted in Poland confirmed that treatment with trastuzumab-anns was associated with an acceptable cardiac safety profile, even when switching from trastuzumab reference or when combined with pertuzumab. Read More ›

Preliminary findings of this retrospective study indicate that treatment with bevacizumab reference product may be associated with a higher risk for hypertension and proteinuria, whereas treatment with bevacizumab biosimilars correlated with shorter onset of these adverse events. Read More ›

The results of the cost-efficiency analysis within the Centers for Medicare & Medicaid Services Oncology Care Model indicate that switching from reference pegfilgrastim to pegfilgrastim-jmdb provided cost-savings that could potentially be reallocated to food and transportation support. Read More ›

A real-world retrospective study (Canadian population) showed that patients with HER2-positive neoadjuvant early breast cancer treated with trastuzumab-dkst versus trastuzumab achieved similar pCR rates. Read More ›

Patients who take immune checkpoint inhibitors experience a small number of severe side effects, although the majority of them recover with treatment. Read More ›

Sotorasib and adagrasib show promising clinical activity against KRAS^G12C mutations in patients with NSCLC, giving new hope for patients with the previously regarded “undruggable” disease. Read More ›

A subgroup analysis of the CodeBreaK 100 trial results found that sotorasib achieved a positive response in pretreated patients with KRAS^G12C mutation–positive NSCLC subtypes. Read More ›

A recently released retrospective study demonstrates that NSAID use in patients with NSCLC enhances immune checkpoint efficacy. Read More ›

Differences in tumor immune microenvironment, including immune cells infiltrated in tumors and PD-L1 expression, show links to the divergent response to immune checkpoint inhibitors in patients with KRAS mutation and STK11 co-mutation. Read More ›

Despite apparent therapeutic efficacy and guideline recommendations, predictive biomarker testing and subsequent first-line targeted therapy treatment in patients with NSCLC have not been widely implemented in the community oncology setting. Read More ›